On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in
Pfizer (NYSE: PFE) that's worth approximately $1 billion. Now, Starboard will aim to work with the company's management as well as consult with former executives -- all with the aim of turning around
Pfizer's sagging fortunes.But can bringing in a new group of advisors do much to bolster
Pfizer's competitiveness? Was there actually anything wrong with the strategy it was pursuing before, or was it merely in a transitional period where the market wasn't valuing its stock correctly? And how will this new development affect the stock for today's shareholders?Let's drill down and answer each of these questions in detail.Continue reading
Weiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool